{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,1,17]],"date-time":"2026-01-17T04:21:54Z","timestamp":1768623714153,"version":"3.49.0"},"reference-count":27,"publisher":"Elsevier BV","issue":"6","license":[{"start":{"date-parts":[[2009,6,1]],"date-time":"2009-06-01T00:00:00Z","timestamp":1243814400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Bone"],"published-print":{"date-parts":[[2009,6]]},"DOI":"10.1016\/j.bone.2009.02.016","type":"journal-article","created":{"date-parts":[[2009,3,3]],"date-time":"2009-03-03T09:16:49Z","timestamp":1236071809000},"page":"1078-1084","source":"Crossref","is-referenced-by-count":48,"title":["A double-blinded head-to-head trial of minodronate and alendronate in women with postmenopausal osteoporosis"],"prefix":"10.1016","volume":"44","author":[{"given":"Hiroshi","family":"Hagino","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yoshiki","family":"Nishizawa","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Teruki","family":"Sone","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hirotoshi","family":"Morii","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yuji","family":"Taketani","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Toshitaka","family":"Nakamura","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Akira","family":"Itabashi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hideaki","family":"Mizunuma","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yasuo","family":"Ohashi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Masataka","family":"Shiraki","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Toshiomi","family":"Minamide","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Toshio","family":"Matsumoto","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.bone.2009.02.016_bib1","series-title":"Bisphospjonates in bone disease: from the Laboratory to the patient","first-page":"27","article-title":"Bisphosphonates\u2014preclinical","author":"Fleisch","year":"2000"},{"key":"10.1016\/j.bone.2009.02.016_bib2","doi-asserted-by":"crossref","first-page":"235","DOI":"10.1016\/S0022-3565(24)38786-5","article-title":"Structure\u2013activity relationships for inhibition of farnesyl diphosphate synthase in vitro and inhibition of bone resorption in vivo by nitrogen-containing bisphosphonates","volume":"296","author":"Dunford","year":"2001","journal-title":"J. Pharmacol. Exp. Ther."},{"issue":"Suppl","key":"10.1016\/j.bone.2009.02.016_bib3","first-page":"S471","article-title":"A randomized controlled trial with ONO-5920 (minodronate\/YM529) in Japanese patients with postmenopausal osteoporosis","volume":"17","author":"Morii","year":"2002","journal-title":"J. Bone. Miner. Res."},{"key":"10.1016\/j.bone.2009.02.016_bib4","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1359\/jbmr.2002.17.1.1","article-title":"Relationships between bone mineral density and incident vertebral fracture risk with raloxifene therapy","volume":"17","author":"Sarkar","year":"2002","journal-title":"J. Bone. Miner. Res."},{"key":"10.1016\/j.bone.2009.02.016_bib5","doi-asserted-by":"crossref","first-page":"1250","DOI":"10.1359\/JBMR.040512","article-title":"Change in bone turnover and hip, non-spine, and vertebral fracture in alendronate-treated women: the fracture intervention trial","volume":"19","author":"Bauer","year":"2004","journal-title":"J. Bone. Miner. Res."},{"key":"10.1016\/j.bone.2009.02.016_bib6","doi-asserted-by":"crossref","first-page":"139","DOI":"10.1007\/s007740050038","article-title":"Diagnostic criteria of primary osteoporosis. The Committee of the Japanese Society for Bone and Mineral Research for Development of Diagnostic Criteria of Osteoporosis","volume":"16","author":"Orimo","year":"1998","journal-title":"J. Bone. Miner. Metab."},{"key":"10.1016\/j.bone.2009.02.016_bib7","doi-asserted-by":"crossref","first-page":"331","DOI":"10.1007\/s007740170001","article-title":"Diagnostic criteria for primary osteoporosis: year 2000 revision","volume":"19","author":"Orimo","year":"2001","journal-title":"J. Bone. Miner. Metab."},{"key":"10.1016\/j.bone.2009.02.016_bib8","doi-asserted-by":"crossref","first-page":"43","DOI":"10.1016\/S0378-4347(00)83378-2","article-title":"Rapid assay for hard tissue collagen cross-links using isocratic ion-pair reversed-phase liquid chromatography","volume":"525","author":"James","year":"1990","journal-title":"J. Chromatogr."},{"key":"10.1016\/j.bone.2009.02.016_bib9","doi-asserted-by":"crossref","first-page":"1371","DOI":"10.1001\/jama.282.14.1371","article-title":"Users' guides to the medical literature: XIX. Applying clinical trial results B. Guidelines for determining whether a drug is exerting (more than) a class effect","volume":"282","author":"McAlister","year":"1999","journal-title":"Jama"},{"key":"10.1016\/j.bone.2009.02.016_bib10","doi-asserted-by":"crossref","first-page":"771","DOI":"10.1001\/jama.282.8.771","article-title":"Users' guides to the medical literature: XIX. Applying clinical trial results. A. How to use an article measuring the effect of an intervention on surrogate end points. Evidence-Based Medicine Working Group","volume":"282","author":"Bucher","year":"1999","journal-title":"Jama"},{"key":"10.1016\/j.bone.2009.02.016_bib11","doi-asserted-by":"crossref","first-page":"508","DOI":"10.1210\/er.2001-2002","article-title":"Meta-analyses of therapies for postmenopausal osteoporosis. II. Meta-analysis of alendronate for the treatment of postmenopausal women","volume":"23","author":"Cranney","year":"2002","journal-title":"Endocr. Rev."},{"key":"10.1016\/j.bone.2009.02.016_bib12","doi-asserted-by":"crossref","first-page":"2077","DOI":"10.1001\/jama.280.24.2077","article-title":"Effect of alendronate on risk of fracture in women with low bone density but without vertebral fractures: results from the Fracture Intervention Trial","volume":"280","author":"Cummings","year":"1998","journal-title":"Jama"},{"key":"10.1016\/j.bone.2009.02.016_bib13","doi-asserted-by":"crossref","first-page":"1535","DOI":"10.1016\/S0140-6736(96)07088-2","article-title":"Randomised trial of effect of alendronate on risk of fracture in women with existing vertebral fractures. Fracture Intervention Trial Research Group","volume":"348","author":"Black","year":"1996","journal-title":"Lancet"},{"key":"10.1016\/j.bone.2009.02.016_bib14","doi-asserted-by":"crossref","first-page":"63","DOI":"10.2165\/00044011-200626020-00002","article-title":"Alendronic acid produces greater effects than risedronic acid on bone density and turnover in postmenopausal women with osteoporosis: results of FACTS-International","volume":"26","author":"Reid","year":"2006","journal-title":"Clin. Drug. Investig."},{"key":"10.1016\/j.bone.2009.02.016_bib15","doi-asserted-by":"crossref","first-page":"141","DOI":"10.1359\/JBMR.040920","article-title":"Treatment with once-weekly alendronate 70\u00a0mg compared with once-weekly risedronate 35\u00a0mg in women with postmenopausal osteoporosis: a randomized double-blind study","volume":"20","author":"Rosen","year":"2005","journal-title":"J. Bone. Miner. Res."},{"key":"10.1016\/j.bone.2009.02.016_bib16","doi-asserted-by":"crossref","first-page":"1586","DOI":"10.1210\/jc.87.4.1586","article-title":"Changes in bone density and turnover explain the reductions in incidence of nonvertebral fractures that occur during treatment with antiresorptive agents","volume":"87","author":"Hochberg","year":"2002","journal-title":"J. Clin. Endocrinol. Metab."},{"key":"10.1016\/j.bone.2009.02.016_bib17","doi-asserted-by":"crossref","first-page":"1051","DOI":"10.1359\/jbmr.2003.18.6.1051","article-title":"Relationship of early changes in bone resorption to the reduction in fracture risk with risedronate","volume":"18","author":"Eastell","year":"2003","journal-title":"J. Bone. Miner. Res."},{"key":"10.1016\/j.bone.2009.02.016_bib18","doi-asserted-by":"crossref","first-page":"1146","DOI":"10.1359\/jbmr.2003.18.6.1146","article-title":"Surrogates for fracture endpoints in clinical trials","volume":"18","author":"Khosla","year":"2003","journal-title":"J. Bone. Miner. Res."},{"key":"10.1016\/j.bone.2009.02.016_bib19","doi-asserted-by":"crossref","first-page":"183","DOI":"10.1007\/s001980050214","article-title":"A double-masked multicenter comparative study between alendronate and alfacalcidol in Japanese patients with osteoporosis. The Alendronate Phase III Osteoporosis Treatment Research Group","volume":"10","author":"Shiraki","year":"1999","journal-title":"Osteoporos. Int."},{"key":"10.1016\/j.bone.2009.02.016_bib20","doi-asserted-by":"crossref","first-page":"382","DOI":"10.1007\/s00774-005-0616-5","article-title":"Therapeutic effects of alendronate 35\u00a0mg once weekly and 5\u00a0mg once daily in Japanese patients with osteoporosis: a double-blind, randomized study","volume":"23","author":"Uchida","year":"2005","journal-title":"J. Bone. Miner. Metab."},{"key":"10.1016\/j.bone.2009.02.016_bib21","doi-asserted-by":"crossref","first-page":"971","DOI":"10.1007\/s001980200135","article-title":"A comparison of the effect of risedronate and etidronate on lumbar bone mineral density in Japanese patients with osteoporosis: a randomized controlled trial","volume":"13","author":"Fukunaga","year":"2002","journal-title":"Osteoporos. Int."},{"key":"10.1016\/j.bone.2009.02.016_bib22","doi-asserted-by":"crossref","first-page":"265","DOI":"10.1210\/jc.82.1.265","article-title":"Dose\u2013response relationships for alendronate treatment in osteoporotic elderly women. Alendronate Elderly Osteoporosis Study Centers","volume":"82","author":"Bone","year":"1997","journal-title":"J. Clin. Endocrinol. Metab."},{"key":"10.1016\/j.bone.2009.02.016_bib23","doi-asserted-by":"crossref","first-page":"488","DOI":"10.1016\/S0002-9343(96)00282-3","article-title":"Effect of three years of oral alendronate treatment in postmenopausal women with osteoporosis","volume":"101","author":"Tucci","year":"1996","journal-title":"Am. J. Med."},{"key":"10.1016\/j.bone.2009.02.016_bib24","doi-asserted-by":"crossref","first-page":"141","DOI":"10.1016\/8756-3282(95)00436-X","article-title":"Oral alendronate induces progressive increases in bone mass of the spine, hip, and total body over 3\u00a0years in postmenopausal women with osteoporosis","volume":"18","author":"Devogelaer","year":"1996","journal-title":"Bone"},{"key":"10.1016\/j.bone.2009.02.016_bib25","doi-asserted-by":"crossref","first-page":"455","DOI":"10.1007\/s001980050171","article-title":"Skeletal benefits of two years of alendronate treatment are similar for early postmenopausal Asian and Caucasian women","volume":"9","author":"Wasnich","year":"1999","journal-title":"Osteoporos. Int."},{"key":"10.1016\/j.bone.2009.02.016_bib26","doi-asserted-by":"crossref","first-page":"461","DOI":"10.1007\/PL00004171","article-title":"Multinational, placebo-controlled, randomized trial of the effects of alendronate on bone density and fracture risk in postmenopausal women with low bone mass: results of the FOSIT study. Fosamax International Trial Study Group","volume":"9","author":"Pols","year":"1999","journal-title":"Osteoporos. Int."},{"key":"10.1016\/j.bone.2009.02.016_bib27","first-page":"1","article-title":"Therapeutic equivalence of alendronate 70\u00a0mg once-weekly and alendronate 10\u00a0mg daily in the treatment of osteoporosis. Alendronate Once-Weekly Study Group","volume":"12","author":"Schnitzer","year":"2000","journal-title":"Aging. (Milano)."}],"container-title":["Bone"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S8756328209005201?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S8756328209005201?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,2,7]],"date-time":"2025-02-07T23:44:14Z","timestamp":1738971854000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S8756328209005201"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2009,6]]},"references-count":27,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2009,6]]}},"alternative-id":["S8756328209005201"],"URL":"https:\/\/doi.org\/10.1016\/j.bone.2009.02.016","relation":{},"ISSN":["8756-3282"],"issn-type":[{"value":"8756-3282","type":"print"}],"subject":[],"published":{"date-parts":[[2009,6]]}}}